Naturalistic comparison of clomethiazole and Diazepam treatment in alcohol withdrawal: effects on oxidative stress, inflammatory cytokines and hepatic biomarkers.
Alcohol detoxification
Alcohol withdrawal treatment
Carbohydrate-deficient transferrin
Clomethiazole
Diazepam
Dityrosine
Ethyl glucuronide
Inflammation
Malondialdehyde
Phosphatidylethanol
Transaminases
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
28
03
2024
accepted:
27
05
2024
medline:
9
6
2024
pubmed:
9
6
2024
entrez:
8
6
2024
Statut:
aheadofprint
Résumé
Ethanol is metabolized by alcohol dehydrogenase to acetaldehyde and induces cytochrome P450 2E1 (CYP2E1), which generates reactive oxygen species that cause inflammatory liver damage. Clomethiazole, a drug approved for alcohol withdrawal treatment (AWT) in some European countries, inhibits CYP2E1. We hypothesized that clomethiazole would lead to a faster reduction in oxidative stress, inflammatory cytokines, and liver enzymes compared to diazepam treatment. We analysed respective biomarkers in 50 patients undergoing AWT and 25 healthy individuals but found no statistical difference between the two medication groups over 3-5 days. Hence, our hypothesis was not confirmed during this observation period.
Identifiants
pubmed: 38851655
doi: 10.1007/s00406-024-01835-7
pii: 10.1007/s00406-024-01835-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cheplapharm Arzeimittel (DE)
ID : CMZ study
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization (2018) Global status report on alcohol and health 2018. World Health Organization, Geneva
Seitz HK, Bataller R, Cortez-Pinto H et al (2018) Alcoholic liver disease. Nat Rev Dis Primer 4:16. https://doi.org/10.1038/s41572-018-0014-7
doi: 10.1038/s41572-018-0014-7
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT) (2020) “Screening, Diagnose und Behandlung alkoholbezogener Störungen”
Müller UJ, Schuermann F, Dobrowolny H et al (2016) Assessment of pharmacological treatment quality: comparison of symptom-triggered vs. fixed-schedule alcohol withdrawal in clinical practice. Pharmacopsychiatry 49:199–203. https://doi.org/10.1055/s-0042-104508
doi: 10.1055/s-0042-104508
pubmed: 27101233
Bahji A, Bach P, Danilewitz M et al (2022) Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction 117:2591–2601. https://doi.org/10.1111/add.15853
doi: 10.1111/add.15853
pubmed: 35194860
pmcid: 9969997
Stresser DM, Perloff ES, Mason AK et al (2016) Selective time- and NADPH-dependent inhibition of human CYP2E1 by clomethiazole. Drug Metab Dispos 44:1424–1430. https://doi.org/10.1124/dmd.116.070193
doi: 10.1124/dmd.116.070193
pubmed: 27149898
Harmon D, Coleman E, Marshall C et al (2003) The effect of clomethiazole on plasma concentrations of interleukin-6,-8,-1β, tumor necrosis factor-α, and neutrophil adhesion molecule expression during experimental extracorporeal circulation. Anesth Analg 9:13–18. https://doi.org/10.1213/01.ANE.0000063821.60233.7D
doi: 10.1213/01.ANE.0000063821.60233.7D
Seitz HK, Wang X-D (2013) The role of cytochrome P450 2E1 in ethanol-mediated carcinogenesis. In: Dey A (ed) Cytochrome P450 2E1: its role in disease and drug metabolism. Springer, Dordrecht, pp 131–143
doi: 10.1007/978-94-007-5881-0_3
Saunders JB, Aasland OG, Babor TF et al (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88:791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x
doi: 10.1111/j.1360-0443.1993.tb02093.x
pubmed: 8329970
Anton RF (2000) Obsessive–compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction 95:211–217. https://doi.org/10.1080/09652140050111771
doi: 10.1080/09652140050111771
Wetterling T, Kanitz R-D, Besters B et al (1997) A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol 32:753–760. https://doi.org/10.1093/oxfordjournals.alcalc.a008326
doi: 10.1093/oxfordjournals.alcalc.a008326
pubmed: 9463730
Neumann J, Beck O, Helander A et al (2020) Sensitive determination of ethyl glucuronide in serum and whole blood: detection time after alcohol exposure compared with urine. J Lab Med 44:211–219. https://doi.org/10.1515/labmed-2019-0203
doi: 10.1515/labmed-2019-0203
Neumann J, Beck O, Helander A, Böttcher M (2020) Performance of PEth compared with other alcohol biomarkers in subjects presenting for occupational and pre-employment medical examination. Alcohol Alcohol 55:401–408. https://doi.org/10.1093/alcalc/agaa027
doi: 10.1093/alcalc/agaa027
pubmed: 32363383
pmcid: 7338721
Jordan W, Dobrowolny H, Bahn S et al (2018) Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. Eur Arch Psychiatry Clin Neurosci 268:129–143. https://doi.org/10.1007/s00406-016-0749-7
doi: 10.1007/s00406-016-0749-7
pubmed: 27913877
Seitz HK, Lieber CS, Simanowski UA et al (2000) Handbuch Alkohol, Alkoholismus, alkoholbedingte Organschäden, 2, neubearb. Barth, Heidelberg, pp 516–538
Hohmann N, Schröder F, Moreira B et al (2022) Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. Gut 71:842–844. https://doi.org/10.1136/gutjnl-2021-324727
doi: 10.1136/gutjnl-2021-324727
pubmed: 33972357
Hohmann N, Schröder F, Moreira B et al (2023) Effect of clomethiazole vs. clorazepate on hepatic fat and serum transaminase activities in alcohol-associated liver disease: results from a randomized, controlled phase II clinical trial. Alcohol Alcohol 58:134–141. https://doi.org/10.1093/alcalc/agac068
doi: 10.1093/alcalc/agac068
pubmed: 36562601
Haukeland JW, Schreiner LT, Lorgen I et al (2008) ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol 43:1241–1248. https://doi.org/10.1080/00365520802158614
doi: 10.1080/00365520802158614
pubmed: 18609128